Visualization of Gerota Fascia Involved With Metastatic Melanoma on FDG PET/CT.

Clin Nucl MedAug 24, 2026 (epub)
Case ReportRadiology (Diagnostic)Oncology (Medical)

Gary A Ulaner, Pete Giuliano

✦ AI-curated · Sources linked

Case in brief

A 67-year-old man with melanoma underwent FDG PET/CT, which showed FDG-avid curvilinear soft tissue anterior, lateral, and posterior to the left kidney. The structure was identified as Gerota fascia, the fibrous sheath surrounding the kidneys, adrenal glands, and adjacent fat, and was involved by metastatic melanoma. The finding demonstrated the fascia’s appearance when affected by malignancy on FDG PET/CT.

What made this case unusual

Gerota fascia, which is not commonly visualized on FDG PET/CT, appeared as FDG-avid curvilinear soft tissue around the kidney because of metastatic involvement.

Diagnostic / clinical pearl

Recognizing the location and expected appearance of Gerota fascia can help identify it when pathologically involved on FDG PET/CT.

Source

PubMed · PMID 42640599

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Radiology (Diagnostic)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.